Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442507 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00442507: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT00442507 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00442507, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction
Primary Outcome
* TTP is defined as the time from initiation of treatment to the date of documented progression. * The median of TTP with 95% confidence interval will be presented. * Progressive disease (target lesions) is defined as at least a 20% increase in the sum of the longest diameter of the target lesions taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. * Progressive disease (non-target lesions) is defined as appeara
Interventions
- DRUG Erlotinib
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Why NCT00442507 stopped before completion
NCT00442507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00442507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00442507 about?
NCT00442507 is a clinical study titled "Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction". Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction
What is the current status of trial NCT00442507?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2007-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00442507?
The interventions under investigation include: Erlotinib (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00442507?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00442507's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia